After two first-in-class approvals, the question is no longer which inhaler. It is which triple-therapy failure phenotype a payer will pay to treat.
A large diagnosed population sits alongside substantial underdiagnosis, with only a minority of higher-risk adults ever tested. Diagnosis is spirometric and patients are staged by a system that identifies exacerbators as a distinct group. Because the commercially interesting population is the exacerbating one, spirometry rates rather than prevalence set the reachable pool.
Two first-in-class add-ons ended a decade in which competition was between single-inhaler triples. They do not compete head to head. One is a non-steroidal add-on usable at any step; the other is a biologic gated to an eosinophil-defined endotype on maximal triple therapy. The contest is therefore not between two products for one patient, but between two definitions of which failure phenotype warrants an add-on at all.
A single laboratory value routes the patient. The biologic requires prior authorisation gated on a blood eosinophil threshold, on triple therapy, with documented exacerbations; the other faces new-to-market controls instead. That makes eosinophil testing rates a commercial variable rather than a clinical detail. The pivotal exacerbation reductions for both add-ons clear the incumbent triple benchmark, but they are not head-to-head and the populations differ, so they cannot be read as a ranking - which moves the argument to which population a payer accepts.
AXLRx COPD reports size the endotype pools separately and map where the two entrants overlap, stack, or leave room for the oral niche.
Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk.
Ensifentrine and dupilumab, both approved in 2024, already own the exacerbator add-on tier. A new entrant must clear a 31-41% exacerbation-reduction bar and pick a phenotype-agnostic or eosinophil-gated lane before it competes on anything else.
About 14 million US adults carry a COPD diagnosis, and the condition is a leading cause of death, but underdiagnosis is substantial: only 41.4% of higher-risk adults have been tested. Diagnosis is spirometric, at an FEV1 to FVC ratio below 0.70, and patients are staged by the GOLD A to E system, where group E identifies exacerbators. Because the commercially interesting population is the exacerbating one, spirometry rates rather than prevalence set the reachable pool.
Two first-in-class add-ons ended a decade in which the contest was between inhalers. Ensifentrine, the first novel inhaled mechanism in more than twenty years, was approved in June 2024, and dupilumab, the first biologic ever approved in COPD, in September. They do not compete head to head: ensifentrine is a non-steroidal add-on usable at any step, while dupilumab is gated to the eosinophilic endotype on maximal triple therapy. The question has moved from device and formulary tier to which failure phenotype a payer will pay to treat.
It decides which of the two 2024 entrants a patient can reach. Dupilumab requires prior authorisation gated on a blood eosinophil count of 300 cells per microlitre or above, on triple therapy, with a documented exacerbation history; ensifentrine is phenotype-agnostic and faces new-to-market controls instead. A single laboratory value therefore routes the patient, which makes eosinophil testing rates in pulmonology and primary care a commercial variable rather than a clinical detail.
Ensifentrine reduced exacerbations by 41% in the pooled ENHANCE trials and dupilumab by 31% in pooled BOREAS and NOTUS, against 25% for the incumbent triple in IMPACT. These are not head-to-head results and the populations differ, so the figures cannot be read as a ranking. What they do establish is that both add-ons clear the incumbent benchmark in their own populations, which moves the argument to which population a payer accepts rather than which number is larger.
Endotype segmentation that sizes the eosinophil-gated and mechanism-agnostic pools separately against the triple-therapy-failure denominator; a sequencing map showing where the two entrants overlap, where they stack, and where oral roflumilast still holds a niche; and a payer read covering Part D routing, the eosinophil prior-authorisation criteria, new-to-market controls and the Part D out-of-pocket cap. Each is scoped to your asset.